Swiss NASH Foundation

If you missed our NASH Symposium - the talks are now online youtu.be/Wgiry0plXCw #livertwitter #nash #nafld

Help me spreading the word @dufour_jf about HCC Day 2026 in Bern and online, on Feb. 26th 2026 cancer-du-foie.ch/en/ register here- shorturl.at/W8Xtl

Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC. Improved time to failure of treatment strategy with #systemic therapy. Positive study, potential novel approach for #intermediate HCC #ESMO25 #ESMOAmbassadors @myESMO

One of the reasons why it is so difficult to maintain weight loss is because adipose issue retains an epigenetic memory of obesity after weight loss. nature.com/articles/s4158…

1) Our manuscript entitled « Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments” was recently released in Gut gut.bmj.com/content/early/… @campani_claudia @CRCordeliers @SRebouissou @GUTJournal_BMJ @TZ_Hirsch @SImbeaud

Read the new @BritSocGastro #GUTGuideline by Suddle et al entitled "British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults" via bit.ly/3UudyX8 @DinaTiniakos #HCC

Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes | Gut gut.bmj.com/content/73/5/8…

Barcelona is walking the walk and getting in their steps today! A great way to experience Barcelona following a fantastic NIT Summit and SLD Think-Tank the last 2 days. Congratulations to @JVLazarus Lazarus and @schattenbergJ, the amazing faculty and all the participants that made it so interactive and collaborative! @AASLDtweets @EASLnews #sldthinktank @CASLupdates #livertwitter #liverx

#GUTImages from the paper by @AngeloArmandi et al on "Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/49y90Dd @DinaTiniakos @lucavalenti75 @lmiele74 @hanneshagstrom @mromerogomez

#BREAKING It is a big day for the Liver Community! Madrigal is proud to announce the first and only @US_FDA-approved therapy in NASH/MASH. Learn more here: bit.ly/3Pmyqwr #FDAApproval #NASH

A pleasure to give the annual prize of the Swiss Foundation against Liver Cancer to Dr Melloul and Dr Martin for their work on HCC burden and liver resection. ⁦@EmmanuelMelloul⁩ ⁦@InfoCancerFoie⁩ ⁦@CHUVLausanne⁩

Free Debrief on HCC with @SaborowskiAnna, K. Kelley, R. Finn, R. Lencioni, P. Galle on 29th of February Program&registration l1nq.com/188kp @InfoCancerFoie

We wish you a healthy and happy new year! #livertwitter

Obese diabetes patients with [non-alcoholic] fatty liver disease and related chronic liver disease ask me if they have to avoid "rice" from their diet. We are a predominantly rice consuming population, which means, there will be great inertia about getting rice out of the daily diet. Good news is, there is absolutely no need to avoid rice from diet in people with diabetes, obesity and chronic liver disease. Rice contains about 80% starch and is generally considered a high glycaemic index food. GIycemic index is a measure of glucose uptake upon digestion (or postprandial glucose), resulting in a sudden spike in blood glucose content. There is simple hack to enjoy rice with a reduced glucose spike and stress on glycemic status. Cook rice. But do not eat it immediately. Refrigerate it at a minimum of 4°C. That is, let it cool for 24 hours. Reheat and consume it the next day. During the cooling of cooked rice, the structure of the starch in rice takes on a crystalline form that can resist enzymatic digestion in the small intestine for up to three hours - that is cooled rice gains "resistant starch" which is digested more slowly and with lower glucose spikes. So enjoy your daily portion of rice within the calculated calorie content and do not completely remove it from diet. Sources: [1] insider.com/cooling-rice-a… [2] iifiir.org/en/news/refrig…

Merry Xmas and happy and healthy holidays to all of you 🤶

not even 2 hours till our NASH Symposium healthbook.org/webinars/virtu… #NASH #NAFLD #LiverTwitter

Impressive review of trial and real life data on systemic therapy options for HCC by ⁦@SaborowskiAnna⁩ at the ⁦@SASL_School⁩. Brilliant!

Join us on the 30. November 2023 for our Symposium "2023 a pivotal year for NASH" you find the agenda here: swissnashfoundation.org/events/ #nash #nafld #LiverTwitter #LiverX

The registration is open for the upcoming virtual symposium „2023 - a pivotal year for NASH“ please join us for talks and discussions with international experts! #NASH #NAFLD #LiverTwitter healthbook.org/webinars/virtu…

#GUTAbstract by Zhang & @TerryYip12 on "Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation..." via bit.ly/49b1uz4 Paper: bit.ly/49aAArq @wonglaihung @LeeLingLim1 @VWSWong